Cadila Pharmaceuticals hosted Krasnodar Deputy Governor Alexander Ruppel to explore pharma trade, joint ventures, APIs, vaccines and biosimilar opportunities between India and Russia.
Ahmedabad: India’s leading pharmaceutical enterprise, Cadila Pharmaceuticals, hosted the Deputy Governor of Krasnodar Region, Russia, Alexander Ruppel, at its corporate facility in Bhat-Dholka today to explore ways to expand bilateral cooperation between India and Russia in the pharmaceutical sector. The delegation met with senior executives to discuss collaborative growth, trade opportunities, and international healthcare solutions between both nations.
Commenting on the visit, Dr. Sunil Kumar Singh, Assistant Vice President (Head of Representation – Russia), Cadila Pharmaceuticals, stated: “We are honored to host the Russian delegation and explore deeper strategic alignment between India and Russia. This visit opens vital pathways to broaden international export footprint and address evolving global healthcare demands for both countries. We look forward to driving long-term value for patients worldwide with affordable healthcare solutions.”
The discussions explored several core focus areas, including technical exchange, export expansion, and strategic market access. Both nations highlighted the importance of establishing dependable healthcare supply chains to ensure uninterrupted access to essential medicines in various international markets.
Emphasizing the economic and diplomatic significance of the engagement, Deputy Governor of Krasnodar Region, Russia, Alexander Ruppel, said, “This visit marks a key milestone in reinforcing the bilateral relationship between Russia and India. India’s pharmaceutical expertise is globally recognized, and we see strong potential to explore each other’s markets. By focusing on localized production and exploring joint ventures in biosimilars, vaccines, and active pharmaceutical ingredients (APIs), both nations can unlock immense market potential and foster sustainable healthcare innovation.”
The visit concluded on a promising note, with leadership from both sides reaffirming their dedication to actionable collaboration. Through mutual investment and shared expertise, India and Russia continue to build a resilient partnership aimed at advancing global health and economic prosperity.
About Cadila Pharmaceuticals: Cadila Pharmaceuticals is one of India’s largest privately held pharmaceutical companies with a global presence across formulations, active pharmaceutical ingredients (APIs), biologics, consumer healthcare, and specialty products. The company operates state-of-the-art manufacturing facilities and serves patients across multiple international markets through its commitment to quality, innovation, and affordability.
